Back

Restoring neurovascular coupling in Alzheimer's disease tauopathy through M1 mAChR modulation

Bassiouni, W.; Abdelnaby, M.; Ai, E.-H.; Abd-Elrahman, K. S.

2026-08-23 pharmacology and toxicology
10.64898/2026.08.18.745579 bioRxiv
Show abstract

Alzheimer's disease is characterized by progressive cognitive decline and early cerebrovascular dysfunction, including impaired neurovascular coupling (NVC) and reduced cerebral blood flow (CBF). Tau pathology is a major driver of these deficits, yet therapeutic strategies targeting tau-induced neurovascular dysfunction remain limited. The M1 muscarinic acetylcholine receptor (M1 mAChR) is a promising therapeutic target because of its critical role in cognition. We previously demonstrated that pharmacological activation of M1 mAChR improves cognitive function and neuronal survival in amyloid-based Alzheimer's disease mouse models through sex-specific mechanisms. However, whether M1 mAChR activation restores tau-mediated NVC deficits remains unknown. P301S mice were used as a model of tauopathy. Cognitive function was evaluated using the novel object recognition and Morris water maze tests, and NVC was assessed by measuring whisker stimulation-induced changes in CBF using laser speckle contrast imaging. Following baseline measurements, mice received an acute intraperitoneal injection of VU0486846, a selective M1 mAChR positive allosteric modulator (3 mg/kg), and CBF responses were reassessed over time. P301S tau mice exhibited impaired recognition and spatial memory functions, associated with reduced whisker stimulation-induced increase in CBF, indicative of impaired NVC response, while acute treatment with VU0486846 reversed these changes in NVC. This rescuing effect of VU0486846 was observed earlier in female tau mice compared to males, suggesting a sex-biased effect of M1 mAChR modulation. These findings demonstrate that M1 mAChR positive allosteric modulation reverses tau-induced neurovascular dysfunction, supporting M1 mAChR activation as a promising disease-modifying approach for Alzheimer's disease. The earlier improvement observed in females further suggests that therapeutic efficacy is influenced by biological sex.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.